Home Health Care Provider Networks: Are Insurers Better Off?
Article
Licensed
Unlicensed Requires Authentication

Health Care Provider Networks: Are Insurers Better Off?

  • Michel Mougeot and Florence Naegelen ORCID logo EMAIL logo
Published/Copyright: August 2, 2022

Abstract

Certain health insurers offer a free choice of providers and an identical copayment regardless of the provider. Others build networks and use selective contracting and financial incentives to channel policyholders to contracted suppliers. In the case of unregulated prices, we compare these two policies when the off-network medical service is not covered. We show how policy ranking depends on the characteristics of demand. If demand is linear, a for-profit insurer and a not-for-profit insurer obtain a higher profit and utility under selective contracting than under uniform reimbursement. In the constant elasticity case, these results do not hold. Insurers prefer uniform reimbursement while consumers are better off under selective contracting in both cases.

JEL Classification: D43; L13; L31; I11; I14

Corresponding author: Florence Naegelen, CRESE, University of Bourgogne-Franche-Comte, Besancon, France, E-mail:

Acknowledgement

We thank an anonymous reviewer and the Editor in Chief for their very helpful comments. The usual disclaimer applies.

Appendix A

Taking Proposition 1 into account, providers’ profits and policyholders’ net utility are respectively given by

Π 1 s = Π 2 s = Π s = ( ( α c ) ( 1 γ ) ( 4 + 2 γ γ 2 ) k γ ( 2 γ 2 ) γ X ) 2 4 ( 4 γ 2 ) 2 ( 1 γ 2 )
U ̄ s = 2 k ( α c ) ( 1 γ ) ( 16 + 20 γ 8 γ 2 17 γ 3 γ 4 + 3 γ 5 ) + ( α c ) 2 ( 16 + 8 γ 16 γ 2 18 γ 3 + 5 γ 4 + 8 γ 5 3 γ 6 ) + k 2 ( 2 γ 2 ) 2 ( 4 3 γ 2 ) + X ( α c ) ( 1 γ ) ( 8 + 12 γ + 2 γ 2 3 γ 3 ) k ( 8 10 γ 2 + 3 γ 4 ) / ( 4 ( 4 γ 2 ) ( 4 5 γ 2 + γ 4 ) ) .

From the insurer’s point of view, the cost incurred and the total net utility are respectively given by

C s = k ( ( α c ) ( 1 γ ) ( 4 + γ 3 ) + k ( 2 γ 2 ) 2 + ( 2 γ 2 ) X ) 2 ( 4 γ 2 ) ( 1 γ 2 ) V s = ( α c ) 2 ( 1 γ ) ( 16 + 24 γ + 8 γ 2 10 γ 3 5 γ 4 + 3 γ 5 ) k 2 ( 16 12 γ 2 + γ 6 ) + 2 k ( α c ) γ ( 4 8 γ 5 γ 2 + 8 γ 3 + 3 γ 4 2 γ 5 ) + X ( ( α c ) ( 8 + 4 γ 10 γ 2 5 γ 3 + 3 γ 4 ) k ( 8 2 γ 2 γ 4 ) ) / ( 4 ( 4 γ 2 ) ( 4 5 γ 2 + γ 4 ) ) .
Appendix B

To prove that ΔV = V s VB > 0 when k k ̂ , we have to show that ΔV is strictly concave in k. The second derivative of ΔV has the same sign as a sum

2 ( 8 2 γ 2 + γ 3 ) ( 4 4 γ 2 γ 2 + γ 3 ) X 3 / 2 + Y

where Y < 0 if k < k ̂ and 4 − 4γ − 2γ2 + γ3 < 0 if γ > 0.806. So, when k < k ̂ and γ > 0.806, the second derivative is negative. Replacing X with ( 4 ( α c ) ( 1 γ ) γ + k ( 2 γ 2 ) ) 2 > X , we obtain a sum of negative terms for any γ and k < k ̂ . Consequently, ΔV is strictly concave in k when k < k ̂ . As ΔV > 0 when k = 0 and ΔV > 0 when k = k ̂ , ΔV > 0 for any k < k ̂ .

Appendix C

The right-hand member of (12) is defined if c/(βρ) ≥ p2 > c/β and is positive when c > k. The left-hand member of (12) is positive if p 2 A = p 2 = c ( 2 β ρ ( 1 + β ) ( 1 β ) ( 4 8 β ρ + 5 β 2 ρ 2 β 3 ρ 2 ) 2 β ( 1 + ρ ( 1 2 β ) ) ) , p 2 + = c ( 2 β ρ ( 1 + β ) + ( 1 β ) ( 4 8 β ρ + 5 β 2 ρ 2 β 3 ρ 2 ) 2 β ( 1 + ρ ( 1 2 β ) ) ) . Thus, p2 solution of (12) belongs to [ c / β , p 2 + . The left-hand member of the equality is decreasing and concave when p2A. It is equal to c2(1 − β)(1 − ρ)/β when p2 = c/β and to 0 when p 2 = p 2 + . The right-hand member of (12) is decreasing and convex in this interval. It tends to + when p2 tends to c/β and is positive when p 2 = p 2 + , as c / ( β ρ ) > p 2 + > c / β . It tends to 0 when p2 tends to c/βρ. When c > k, the right-hand member of (12) is positive and (12) has at most two solutions belonging to A. Figure 3 shows the two members of (12) for c = 20, k = 10, β = 1/2, and ρ = 1/2.

Figure 3: 
Right and left-hand members of (12).
Figure 3:

Right and left-hand members of (12).

Moreover, the equilibrium solution must satisfy (10). When k s = k, this imply

(13) β ( 1 + ρ ( 1 2 β ) ) ( 2 β ( 1 + ρ ) ) p 2 ( 1 β ρ ) ( p 2 β c ) ( 1 β ) ( c p 2 β ρ ) 1 β β < ( c k ) .

Taking (12) and (13) into account, we must have p 2 ( β c 2 ) ( 1 + β ρ ) c ( 2 β ( 1 + ρ ) ) p 2 β ( 1 + ρ ( 1 2 β ) ) > 0 , which implies p 2 < p ̄ 2 = c 2 β ( 1 + ρ ) β ( 1 + ρ ( 1 2 β ) ) . As the left-hand member of (12) is higher (resp. lower) than the right-hand member of (12) when p 2 = p ̄ 2 (resp. p2 = c/β), there is only one solution belonging to] c / β , p ̄ 2 .

Appendix D

The equilibrium price is solution of (12). (12) is an implicit equation F(p2,c, k, β, ρ) = 0. For each value of ρ, ρ ∈ {1/2, 3/5, 7/10, 4/5, 9/10}, and β, β ∈ {1/2, 3/5, 7/10, 4/5, 9/10}, using the Mathematica computation program, we can obtain m expressions p2 = Root[F, m] representing the exact root of F(p2,c, k) = 0. Each root is a function of c and k and can be computed for any value of (c, k). Among the m roots, we select the root corresponding to a real value satisfying the constraints c / β < p 2 < p ̄ 2 and c > k” > k and ensuring the highest profit. Using this root and replacing in the implicit function (9), we obtain p1(p2,c, k) for any (β, ρ). Reporting these values in q 1 s , we can calculate q 1 s 2 q B for any c and k < k” and obtain numerical values showing that q 1 s > 2 q B for any c, k, β, and ρ. As an example, let us consider ρ = 1/2 and β = 1/2. (12) becomes

18 c 2 39 c p 2 + 12 p 2 2 ( c k ) ( p 2 4 c ) 2 2 c p 2 = 0

whose Mathematica solution is given by

(14) p 2 = Root [ 20 c 3 16 c 2 k + ( 88 c 2 + 8 c k ) # 1 ( 62 c + k ) # 1 2 + 12 # 1 3 & , 2 ]

where #1 represents the first argument supplied to a pure function. For each couple (c, k), we obtain a value of p2. Replacing (14) in p1, we obtain p1(c, k) and we can calculate q 1 s ( c , k ) and q 1 s ( c , k ) 2 q B . Table 6 summarizes these results when k < k”.

Table 6:

Values of q 1 s ( c , k ) 2 q B .

c\k 1 3 5 7 9 11 13 15 17
2 58.97
4 7.13 86.54
6 2.41 13.63 96.02
8 1.12 5.28 16.79 100.85
10 0.61 2.73 6.90 18.71
12 0.37 1.65 3.72 7.96 20.00
14 0.24 1.09 2.31 4.40 8.73 20.93
16 0.16 0.76 1.56 2.78 4.91 9.31 21.64
18 0.11 0.56 1.12 1.91 3.15 5.31 9.76 22.19
20 0.07 0.42 0.83 1.39 2.19 3.44 5.63 10.12 22.64

For any c and k < k′′, q 1 s ( c , k ) > 2 q B : the insurer’s cost increases when a selective contracting mechanism is implemented. Moreover, this cost increases with the reimbursement k and decreases with the marginal cost c. Similar results are obtained with other values of β and ρ.

References

Anderson, S., A. de Palma, and J.-F. Thisse. 1992. Discrete Choice Theory of Product Differentiation. Cambridge: MIT Press.10.7551/mitpress/2450.001.0001Search in Google Scholar

Barros, P. P., and X. Martinez-Giralt. 2008. “Selecting Health Care Providers: ‘Any Willing Provider’ vs. Negotiation.” European Journal of Political Economy 24 (2): 402–14, https://doi.org/10.1016/j.ejpoleco.2007.10.001.Search in Google Scholar

Berndt, E. R., T. G. McGuire, and J. P. Newhouse. 2011. “A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets.” Forum for Health Economics & Policy 14: 1–30, https://doi.org/10.3386/w16879.Search in Google Scholar

Bernheim, B., and M. Whinston. 1998. “Exclusive Dealing.” Journal of Political Economy 106 (1): 64–103, https://doi.org/10.1086/250003.Search in Google Scholar

Bes, R. E, E. C. Curfs, P. P. Groenewegen, and J. D. de Jong. 2017. “Selective Contracting and Channelling Patients to Preferred Providers: A Scoping Review.” Health Policy 121: 520–14, https://doi.org/10.1016/j.healthpol.2017.03.008.Search in Google Scholar

Boone, J. 2019. “Health Provider Networks with Private Contracts: Is There Under-treatment in Narrow Networks?” Journal of Health Economics 67: 102222, https://doi.org/10.1016/j.jhealeco.2019.102222.Search in Google Scholar

Boone, J., and C. Schottmüller. 2019. “Do Health Insurers Contract the Best Providers? Provider Networks, Quality and Costs.” International Economic Review 60 (3): 1209–47, https://doi.org/10.1111/iere.12383.Search in Google Scholar

Boonen, L. H. H. M., B. Donkers, and F. T. Schut. 2011. “Channeling Consumers to Preferred Providers and the Impact of Status Quo Bias: Does Type of Provider Matter?” Health Services Research 46 (2): 510–30, https://doi.org/10.1111/j.1475-6773.2010.01196.x.Search in Google Scholar

Dixit, A., and J. E. Stiglitz. 1977. “Monopolistic Competition and Optimum Product Diversity.” The American Economic Review 67 (3): 297–308.Search in Google Scholar

Ellison, S. F., and C. M. Snyder. 2010. “Countervailing Power in Wholesale Pharmaceuticals.” The Journal of Industrial Economics 58 (1): 32–53, https://doi.org/10.1111/j.1467-6451.2010.00408.x.Search in Google Scholar

Gal-Or, E. 1997. “Exclusionary Equilibria in Health Care Markets.” Journal of Economics and Management Strategy 6 (1): 5–43, https://doi.org/10.1162/105864097567011.Search in Google Scholar

Martimort, D. 1996. “Exclusive Dealing, Common Agency and Multiprincipals Incentive Theory.” The RAND Journal of Economics 27 (1): 1–31, https://doi.org/10.2307/2555790.Search in Google Scholar

McGuire, T. G. 2012. “Demand for Health Insurance.” In Handbook of Health Economics, Vol. 2, edited by M. Pauly, T. G. McGuire, and P. P. Barros, 317–96. Amsterdam: Elsevier.Search in Google Scholar

Mougeot, M., and F. Naegelen. 2018. “Medical Service Provider Networks.” Health Economics 27: 1201–17, https://doi.org/10.1002/hec.3769.Search in Google Scholar

Siciliani, L., M. Chalkley, and H. Gravelle. 2017. “Policies towards Hospital and GP Competition in Five European Countries.”Health Policy 121: 103–10, https://doi.org/10.1016/j.healthpol.2016.11.011.Search in Google Scholar

Sinaiko, A. D. 2011. “How Do Quality Information and Cost Affect Patient’s Choice of Provider in a Tiered Network Setting? Results from a Survey.” Health Services Research 46 (2): 437–56, https://doi.org/10.1111/j.1475-6773.2010.01217.x.Search in Google Scholar

Singh, N., and X. Vives. 1984. “Price and Quantity Competition in a Differentiated Duopoly.” The RAND Journal of Economics 15 (4): 546–54, https://doi.org/10.2307/2555525.Search in Google Scholar

Spence, M. 1976a. “Product Differentiation and Welfare.” The American Economic Review 66 (2): 407–14.Search in Google Scholar

Spence, M. 1976b. “Product Selection, Fixed Costs and Monopolistic Competition.” The Review of Economic Studies 43 (2): 217–35, https://doi.org/10.2307/2297319.Search in Google Scholar

Vives, X. 2000. Oligopoly Pricing: Old Ideas and New Tools. Cambridge: MIT Press.Search in Google Scholar

Zweifel, P., F. Breyer, and M. Kifmann. 2009. Health Economics. New York: Springer.10.1007/978-3-540-68540-1Search in Google Scholar

Received: 2021-09-22
Revised: 2022-06-27
Accepted: 2022-07-07
Published Online: 2022-08-02
Published in Print: 2022-04-26

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 24.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/rne-2021-0038/html
Scroll to top button